LifeStance Health (LFST) Cash & Equivalents (2020 - 2026)

LifeStance Health has disclosed Cash & Equivalents across 7 years of filings, most recently posting $76.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 42.74% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $76.9 million (down 42.74% YoY), while the FY2025 annual figure was $175.5 million, up 45.19% from the prior year.
• Cash & Equivalents declined to $76.9 million in Q1 2026, from $175.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LFST reached as high as $175.5 million in Q4 2025 and fell as low as $28.5 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $96.7 million (2022), against an average of $96.5 million.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 68.47% — and 2025, when it soared 314.62%.
• A 5-year view of Cash & Equivalents shows it stood at $108.6 million in 2022, then sank by 37.68% to $67.7 million in 2023, then jumped by 78.57% to $120.9 million in 2024, then jumped by 45.19% to $175.5 million in 2025, then tumbled by 56.17% to $76.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $76.9 million, $175.5 million, and $141.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.